This is a patient* with advanced gastric or GEJ adenocarcinoma – someone who knows their situation, but is not surrendering to it.
- Presents with difficulty swallowing
- No prior surgery
- Unresectable stage IV gastric or GEJ adenocarcinoma
- FOLFOX 1L; oxaliplatin dropped after 4 cycles due to low-grade neuropathy
- Disease progressed after 6 months
- Current scan shows metastases in distant lymph nodes and liver
- ECOG PS 1
Can you picture one of your patients? Someone who is determined and counting on you for answers?
CYRAMZA + paclitaxel: The most frequently prescribed regimen in 2L†
CYRAMZA + Paclitaxel Is Proven to Extend Survival, Delay Progression, and Improve Response Rate2 (versus placebo + paclitaxel)
SELECT IMPORTANT SAFETY INFORMATION
The labeling for CYRAMZA contains a Boxed Warning for: hemorrhage and GI hemorrhage, including severe and sometimes fatal events; gastrointestinal (GI) perforation, a potentially fatal event; and impaired wound healing. CYRAMZA should be permanently discontinued in patients who experience severe bleeding or a GI perforation. CYRAMZA should be withheld prior to surgery and discontinued if a patient develops wound healing complications. CYRAMZA contains additional Warnings and Precautions for arterial thromboembolic events, hypertension, infusion-related reactions, clinical deterioration in patients with Child-Pugh B or C cirrhosis, reversible posterior leukoencephalopathy syndrome, proteinuria including nephrotic syndrome, thyroid dysfunction, and embryofetal toxicity. In study 2, the most common adverse reactions observed in patients treated with CYRAMZA plus paclitaxel at a rate of ≥30% and ≥2% higher than placebo plus paclitaxel were fatigue (57% vs 44%), neutropenia (54% vs 31%), diarrhea (32% vs 23%), and epistaxis (31% vs 7%). The most common serious adverse events with CYRAMZA plus paclitaxel in study 2 were neutropenia (3.7%) and febrile neutropenia (2.4%); 19% of patients treated with CYRAMZA plus paclitaxel received granulocyte colony-stimulating factors.
RAINBOW Trial Design (N=665)2,6 The phase III RAINBOW trial evaluated the efficacy and safety of CYRAMZA plus paclitaxel vs placebo plus paclitaxel in patients with locally advanced or metastatic gastric or GE junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- and platinum-containing chemotherapy. Major efficacy outcome measure was overall survival. Supportive efficacy outcome measures were progression-free survival and objective response rate. All patients were Eastern Cooperative Oncology Group performance status 0 or 1. Prior to enrollment, 97% of patients had progressed during treatment or within 4 months after the last dose of first-line chemotherapy for metastatic disease. Twenty-five percent of patients had received anthracycline in combination with platinum/fluoropyrimidine therapy, while 75% did not. Patients were randomized 1:1 to CYRAMZA 8 mg/kg (n=330) or placebo (n=335) every 2 weeks (on days 1 and 15) of each 28-day cycle. Patients in both arms received paclitaxel 80 mg/m2 on days 1, 8, and 15 of each 28-day cycle.
Ramucirumab + paclitaxel: The only FDA-approved combination regimen for the treatment of advanced or metastatic gastric or GEJ adenocarcinoma in the second-line setting and a Category 1 recommendation within the NCCN Guidelines®2-4
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for ramucirumab (CYRAMZA)
CATEGORY 1: Based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate3,4
Second-line treatment trends
Learn about how the second-line treatment landscape has evolved